Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 9Retinoblastoma 4Mesothelioma 4Solid Tumor 3Advanced Solid Tumors 3Advanced Solid Tumor 3Unspecified Adult Solid Tumor, Protocol Specific 2Neoplasms 2Lung Neoplasms 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Thymus Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Solid Tumors, Adult 1Solid Tumor Regardless of Localization and Stage 1Skin Neoplasms 1Select Advanced Solid Tumors 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma 1Salivary Gland Neoplasms 1

Interventions

pembrolizumab 4envafolimab 3Nivolumab 3Injections 2trifluridine tipiracil drug combination 1tebentafusp 1surufatinib 1sintilimab 1linifanib 1fludarabine 1cobimetinib 1TAK-981 1Ipilimumab 1Drug Therapy 1Doxorubicin 1Cyclophosphamide 1Combined Modality Therapy 1Bortezomib 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced or Metastatic Solid Tumors × Drug Therapy × Other solid neoplasm × Clear all
NCT05388279 2023-03-23

A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Terminated
3 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡